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Abstract 
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival 
(PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in 
BRAF V600E/K–mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and 
safety after ≥36-month follow-up for all living patients. 
Patients and methods: This double-blind, phase 3 study enrolled previously untreated patients with BRAF 
V600E/K–mutant unresectable stage IIIC or stage IV melanoma. Patients were randomised to receive dabrafenib 
(150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo. The primary endpoint was PFS; 
secondary endpoints were OS, overall response, duration of response, safety, and pharmacokinetics.   
Results: Between May 4–November 30, 2012, a total of 423 of 947 screened patients were randomly assigned to 
receive dabrafenib plus trametinib (n=211) or dabrafenib monotherapy (n=212). At data cutoff (February 15, 2016), 
outcomes remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% 
with monotherapy, and 3-year OS was 44% versus 32%, respectively. Twenty-five patients receiving monotherapy 
crossed over to combination therapy, with continued follow-up under the monotherapy arm (per intent-to-treat 
principle). Of combination-arm patients alive at 3 years, 58% remained on dabrafenib plus trametinib. Three-year 
OS with the combination reached 62% in the most favourable subgroup (normal lactate dehydrogenase and <3 organ 
sites with metastasis) versus only 25% in the unfavourable subgroup (elevated lactate dehydrogenase). The 
dabrafenib plus trametinib safety profile was consistent with previous clinical trial observations, and no new safety 
signals were detected with long-term use.  
Conclusions: These data demonstrate that durable (≥3 years) survival is achievable with dabrafenib plus trametinib 
in patients with BRAF V600–mutant metastatic melanoma and support long-term first-line use of the combination in 
this setting.  
 
Key words: melanoma, metastatic, BRAF, dabrafenib, trametinib, durable outcomes   
 4 
 
Key message 
Our findings confirm superiority of combination dabrafenib and trametinib, compared with BRAF inhibition alone, 
and establish tolerability of the combination with extended follow-up. These data support long-term use of 
dabrafenib plus trametinib as a standard first-line targeted treatment for patients with BRAF V600–mutant metastatic 
melanoma.  
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Introduction 
Prior to recent therapeutic advances, the prognosis for patients with metastatic melanoma was poor, with a 5-year 
survival of approximately 6% and a median overall survival (OS) of 7.5 months [1]. The anti–cytotoxic T-
lymphocyte-associated protein 4 (anti–CTLA-4) therapy ipilimumab was the first agent to show durable clinical 
benefit lasting ≥5 years in a subset of patients within molecularly unselected advanced melanoma populations [2]. 
More recently, BRAF and MEK inhibitor (BRAFi/MEKi) combinations and anti–programmed death-1 (anti–PD-1) 
checkpoint-inhibitor immunotherapy regimens demonstrated significant improvements in clinical outcomes in phase 
3 trials of patients with metastatic melanoma; however, extended follow-up in these studies has been limited to ≤2 
years [3-9]. Targeted therapies have been purported to be associated with rapid deterioration and death following 
development of secondary resistance; however, evidence from long-term, large randomised studies is lacking. With 
multiple treatments now available for BRAF V600–mutant melanoma, a better understanding of the proportion and 
characteristics of patients who can derive durable benefit and maintain tolerability with long-term use of current 
therapies is needed for optimising treatment.   
 
Combination dabrafenib and trametinib (D+T) demonstrated improved progression-free survival (PFS) and OS over 
BRAFi monotherapy in randomised phase 2 and 3 trials in patients with BRAF V600E/K–mutant stage IIIC 
unresectable or stage IV metastatic melanoma [3, 4, 10-13]. The D+T safety profile has been consistent across these 
studies, in which the combination has been associated with a reduction in hyperproliferative skin lesions (eg, 
squamous cell carcinoma [SCC], keratoacanthoma [KA]) compared with BRAFi monotherapy, while the frequency 
and severity of pyrexia appear higher [3, 4, 10]. 
 
In the most recent analysis of COMBI-d, a randomised, double-blind, phase 3 trial of D+T versus dabrafenib 
monotherapy (dabrafenib plus placebo), with a median follow-up of 20.0 months for the D+T arm and 16.0 months 
for the monotherapy arm, median PFS was 11.0 versus 8.8 months (HR, 0.67; 95% confidence interval [CI], 0.53–
0.84; P=0.0004), median OS was 25.1 versus 18.7 months (HR, 0.71; 95% CI, 0.55–0.92; P=0.0107), and 2-year OS 
was 51% versus 42% [3]. These findings confirmed results from the primary analysis of COMBI-d [12] and were 
consistent with outcomes observed in the randomised phase 3 COMBI-v study of D+T versus vemurafenib [4]. The 
longest follow-up to date for D+T in a randomised study (median, 45.6 months) was reported for the phase 2 
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BRF113220 study (part C) evaluating D+T (n=54) versus dabrafenib monotherapy (n=54) [11], in which D+T-
treated patients had a 2- and 3-year PFS of 25% and 21%, respectively, and a 2- and 3-year OS of 51% and 38%, 
respectively. Pooled data across these trials (median follow-up of 20.0 months) showed that normal baseline serum 
lactate dehydrogenase (LDH) and <3 organ sites containing metastasis were the factors most predictive of durable 
outcomes; patients with both of these characteristics had a 2-year PFS of 46% and a 2-year OS of 75% [14]. 
 
Here, we report an updated 3-year landmark analysis for the phase 3 COMBI-d trial, including updated PFS, OS, 
best response, and safety analyses. 
 
 
Methods 
The COMBI-d study (protocol previously published [3] and further described in the Supplementary Material) was 
continued after prior primary and OS analyses [3, 12] to provide an updated 3-year landmark analysis of long-term 
outcomes. Crossover was permitted following the previous OS analysis by patient/physician discretion on the intent-
to-treat principle, by which any crossover benefit was applied to the randomised therapy arm estimates. Kaplan-
Meier estimations of 2- and 3-year PFS and OS were performed to describe long-term outcomes. Influences of 
prognostic factors on patient-derived benefit were explored with descriptive subgroup stratification by baseline 
factors previously identified as being predictive of outcomes in patients receiving D+T [14]. 
 
 
Results 
Baseline characteristics were well balanced across 423 patients randomly assigned to receive D+T (n=211) or 
dabrafenib monotherapy (n=212; Figure S1; Table S1). At data cutoff, February 15, 2016, patients who were alive 
had ≥36 months of follow-up from time of randomisation. Forty (19%) D+T-arm patients versus 6 (3%) 
monotherapy-arm patients remained on randomised treatment.  
 
At data cutoff, 3-year PFS was 22% for the D+T arm and 12% for the monotherapy arm (HR, 0.71 [95% CI, 0.57–
0.88]) (Figure 1A), and 3-year OS was 44% and 32%, respectively (HR, 0.75 [95% CI, 0.58–0.96]) (Figure 2A). 
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Notably, 25 (12%) patients in the dabrafenib monotherapy arm crossed over to D+T, of which 6 (24%) had 
progressed on monotherapy prior to crossover. Survival outcomes in these crossover patients, all of whom remained 
on D+T as of data cutoff, continued to be followed up under the monotherapy arm. Of combination-arm patients 
who were progression free (n=31) and alive (n=76) at 3 years, 28 (90%) and 44 (58%) remained on D+T, 
respectively. 
 
As expected per the progression rate in each arm, more monotherapy-arm patients received post-progression 
systemic therapy versus D+T-arm patients (130/211 [62%] versus 101/209 [48%]; Table S2). In both the D+T and 
monotherapy groups, immunotherapy was the most common subsequent anticancer therapy (56% versus 56%, 
respectively); ipilimumab was the most common immunotherapy (41% versus 50%), with fewer patients receiving 
nivolumab (7% versus 5%) or pembrolizumab (13% versus 11%).  
 
Long-term PFS and OS consistently favoured D+T over monotherapy, regardless of baseline prognostic factors. 
Three-year PFS rates in patients with normal baseline LDH levels (≤upper limit of normal [ULN], n=273/423 
[65%]) were 27% in the D+T arm versus 17% in the monotherapy arm (HR, 0.70 [95% CI, 0.53–0.93]) (Figure 1B), 
and 3-year OS rates were 54% versus 41%, respectively (HR, 0.74 [95% CI, 0.53–1.03]) (Figure 2B). Of 133 D+T-
arm patients with LDH≤ULN, 61 (46%) were alive at 3 years and 34 (26%) remained on D+T. The greatest clinical 
benefit with D+T was observed in patients with LDH≤ULN and <3 organ sites with metastasis at baseline 
(n=172/423 [41%]), with 3-year PFS rates of 38% in the combination arm versus 16% in the monotherapy arm (HR, 
0.53 [95% CI, 0.38–0.76]) (Figure 1C), and 3-year OS rates of 62% versus 45%, respectively (HR, 0.63 [95% CI, 
0.41–0.99]) (Figure 2C). Of 76 combination-arm patients with baseline LDH≤ULN and <3 organ sites with 
metastasis, 37 (49%) were alive at 3 years and 23 (30%) remained on D+T. In patients with baseline LDH>ULN 
(n=147/423 [35%]), 3-year PFS rates were 13% in the D+T arm and 4% in the monotherapy arm (HR, 0.61 [95% 
CI, 0.43–0.88]) (Figure 1D), and 3-year OS rates were 25% versus 14% (HR, 0.61 [95% CI, 0.41–0.89]) (Figure 
2D). Of 76 D+T-arm patients with LDH>ULN, 15 (20%) were alive at 3 years and 10 (13%) remained on D+T.  
 
The confirmed response rates per Response Evaluation Criteria In Solid Tumors (RECIST) were 68% in 
combination-arm patients versus 55% in monotherapy patients (Table 1), with a complete response (CR) rate of 18% 
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versus 15%, respectively. Median duration of response was 12.0 (95% CI, 9.3–17.1) versus 10.6 (95% CI, 8.3–12.9) 
months.  
 
With a median time on treatment of 11.8 (range, 0.4–43.7) versus 8.3 (range, 0.1–45.3) months in D+T-arm and 
monotherapy-arm patients, respectively, 49% versus 38% had >12 months of study treatment. Adverse events (AEs) 
of any grade, regardless of study drug relationship, were observed in 97% of patients (both arms), with 48% of D+T-
arm patients versus 50% of monotherapy patients experiencing ≥1 grade 3/4 AE (Table S3) and 45% versus 38% 
experiencing serious AEs (Table S4). The incidence of several AEs was higher (>10% difference, any grade) in the 
D+T versus monotherapy arm: pyrexia (59% versus 33%), chills (32% versus 17%), diarrhoea (31% versus 17%), 
vomiting (26% versus 15%), and peripheral oedema (22% vs 9%) (Table S4). Conversely, the incidence of 
hyperkeratosis (35% versus 7%), alopecia (28% versus 9%), and skin papilloma (22% versus 2%) was higher in 
monotherapy-arm versus combination-arm patients (Table S3). Palmoplantar hyperkeratosis (18% versus 5%), 
SCC/KA (7% versus 2%), and basal cell carcinoma (7% versus 4%) also occurred more frequently in monotherapy-
arm versus D+T-arm patients (Table S4). The incidence of other AEs of special interest (ie, cardiotoxicities, ocular 
events, hemorrhages) was generally similar across the study arms (Table S5). 
 
Notably, the frequency of the most common D+T-associated AEs, including pyrexia, did not increase by >2% with 
an additional 13 months of follow-up since the last analysis (Table S6). Similarly, the incidence of key skin-related 
AEs, including palmoplantar hyperkeratosis, SCC/KA, and basal cell carcinoma, did not increase by >1% in the 
combination arm with extended follow-up, and no new primary melanomas were observed. Additionally, occurrence 
of events leading to dose interruptions (n=122; 58%) or permanent discontinuation (n=29; 14%) in D+T-arm 
patients increased by only 2% and 3%, respectively, and no new grade 5 AEs were observed. 
 
Discussion 
This 3-year landmark analysis of COMBI-d represents the longest follow-up for any phase 3 BRAFi/MEKi 
combination therapy trial and provides evidence that long-term clinical benefit and tolerability are achievable with 
D+T in a subset of patients with previously untreated BRAF V600E/K–mutant metastatic melanoma. Importantly, 
these findings do not support the idea that most patients treated by mitogen-activated protein kinase inhibitors 
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rapidly develop deterioration due to secondary resistance. At the 3-year landmark, D+T continued to demonstrate 
superior benefit versus dabrafenib monotherapy (PFS, 22% versus 12%; OS, 44% versus 32%), even though 12% of 
monotherapy patients crossed over to receive D+T. Furthermore, many patients alive at 3 years remained on D+T. 
 
The 3-year OS reported for D+T in this large phase 3 trial (44%) confirms preliminary results for the smaller 
corresponding patient subset in the randomised phase 2 BRF113220 trial (3-year OS, 38%) [11]. More generally, 
survival observed in the current analysis is consistent with previous findings for D+T in BRAF V600–mutant 
melanoma, since the 2-year OS reported here (52%) is similar to that reported in the randomised phase 3 COMBI-v 
study (51%) and in a pooled analysis across registration trials (53%) [14]. In this era of multiple drugs with 
significant activity in metastatic melanoma, clinical trial OS results may be confounded by availability of these 
therapies. In this analysis, of patients who received any post-progression systemic therapy, rates of subsequent anti–
PD-1 use were similar between the D+T and monotherapy arms, and the rate of subsequent ipilimumab therapy was 
numerically higher in the monotherapy arm compared with the D+T arm. Thus, the 3-year OS observed with D+T in 
this study may be mostly attributed to the combination. 
 
Direct comparisons of survival landmarks across trials of currently available melanoma treatments should be 
interpreted with caution due to differences in baseline characteristics between study populations, including the 
requirement for the presence of a BRAF V600E or V600K mutation in targeted therapy trials and the period of time 
during which studies were conducted (eg, what treatments were available for subsequent therapy). However, in the 
absence of prospective head-to-head trials evaluating targeted versus checkpoint-inhibitor immunotherapies, pivotal 
trials to date can be considered to provide outcomes trends for each drug class. Moving forward, it will be important 
to balance advantages of immunotherapy with anti–PD-1 (± anti–CTLA-4) and BRAFi/MEKi combinations.  
 
Follow-up for anti–PD-1 checkpoint-inhibitor immunotherapy regimens has lagged behind targeted therapy; 3-year 
landmark OS results, as reported here, are currently available only for early-phase trials. In a phase 1 study 
evaluating nivolumab monotherapy in 107 patients with previously treated melanoma, unselected for BRAF 
mutation status and 36% with elevated LDH, the 2-, 3-, and 5-year OS rates were 48%, 42%, and 34%, respectively 
[15]. In a phase 1 study of combined nivolumab plus ipilimumab, in 53 treatment-naive (60%) or previously treated 
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(40%) patients with advanced melanoma (38% with elevated LDH), the 3-year OS was 68%; however, it should be 
noted that these results are preliminary [16] and randomized studies of the combination have shown a consistent 2-
year survival of 64% [17], less than this phase 1 landmark. As larger trials evaluating anti–PD-1 regimens in 
metastatic melanoma continue follow-up, preliminary trends in outcomes in a recent meta-analysis demonstrated no 
significant difference in OS between first-line BRAFi/MEKi and anti–PD-1 [18]. 
 
Altogether, data across trials of currently available therapies suggest that long-term survival profiles, at least up to 3 
years, do not seem to confirm the hypothesis that only checkpoint-inhibitor immunotherapy can provide durable 
benefit in patients with metastatic melanoma. Although initial clinical activity (eg, response rates) differs between 
these therapeutic classes [3-9], the proportion of patients with a 3-year benefit may be similar; however this will 
need to be confirmed by additional analyses of checkpoint-inhibitor immunotherapies specifically in patients with 
BRAF-mutant disease. Furthermore, it is important to note that the plateau survival pattern observed with 
ipilimumab [2] has not yet been demonstrated with anti–PD-1 therapies and remains a potential survival pattern for 
BRAFi/MEKi.  
 
It is now well established that efficacy of treatment for metastatic melanoma can differ depending on baseline 
patient characteristics. Analyses of BRAFi–naive patients treated with D+T in the phase 2 BRF113220 study and in 
a pooled analysis across D+T registration trials identified significant associations between baseline LDH and 
number of organ sites containing metastasis and clinical outcomes [11, 14]. Results from the current analysis 
support these findings, with the highest 3-year OS observed among patients with LDH<ULN and <3 organ sites 
containing metastasis (D+T, 62%; monotherapy, 45%). Patients with favourable baseline markers treated with 
frontline D+T are thus more likely to derive long-term benefit from this combination. Moreover, although 3-year 
survival was much lower in patients with LDH>ULN, the superiority of D+T over dabrafenib monotherapy was 
maintained (3-year OS, 25% versus 14%).  
 
With an additional 13 months of follow-up from the previous OS analysis of COMBI-d, CR was achieved by an 
additional 5 D+T-arm patients, resulting in an updated CR rate of 18% and an overall response rate of 68% with the 
combination.  
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The safety profile of D+T with longer follow-up was similar to that observed in previous analyses, in which the 
combination was associated with a reduction in toxicities related to paradoxical activation of the mitogen-activated 
protein kinase pathway compared with BRAFi monotherapy [3, 4, 10-13]. Pyrexia remained the most common AE 
with D+T; however, it has been shown that pyrexia can be managed [19]. The frequency of key AEs did not greatly 
change with additional follow-up, including pyrexia and secondary malignancies, consistent with a recent report that 
incidence of D+T-associated AEs is highest during the first 6 months of treatment, declining thereafter [20]. Thus, 
although patients who remain on and benefit from treatment can become an increasingly biased population due to 
the disappearance of those with very poor tolerance and/or development of secondary resistance, long-term 
treatment with D+T appears to be well tolerated in the subgroup of patients who benefit.  
 
This analysis, representing the longest follow-up for any phase 3 trial evaluating BRAFi/MEKi combination 
therapy, demonstrated that long-term survival is achievable with D+T in a relevant proportion of patients with BRAF 
V600–mutant metastatic melanoma and that long-term treatment with D+T is tolerable, with no new safety signals. 
These results support long-term use of D+T as a first-line treatment strategy for patients with advanced BRAF 
V600–mutant melanoma. However, a more comprehensive model including clinical factors as described here, along 
with molecular and/or immune-markers associated with efficacy is needed to further guide treatment decisions (eg, 
BRAFi/MEKi and checkpoint inhibitor immunotherapy sequencing strategies) in this melanoma population. 
Continued follow-up planned for up to 5 years for COMBI-d will provide further understanding of the extent of 
benefit achievable with D+T in this setting.  
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Figures 
 
Figure 1. Progression-free survival (PFS) in the dabrafenib and trametinib (D+T) and dabrafenib monotherapy 
(D+placebo [Pbo]) arms in (A) the intent-to-treat population and patients with (B) normal baseline lactate 
dehydrogenase (≤upper limit of normal), (C) normal baseline lactate dehydrogenase and <3 organ sites with 
metastasis, and (D) elevated baseline lactate dehydrogenase (>upper limit of normal). CI, confidence interval; HR, 
hazard ratio.  
 
Figure 2. Overall survival (OS) in the dabrafenib and trametinib (D+T) and dabrafenib monotherapy 
(D+placebo [Pbo]) arms in (A) the intent-to-treat population and patients with (B) normal baseline lactate 
dehydrogenase (≤upper limit of normal), (C) normal baseline lactate dehydrogenase and <3 organ sites with 
metastasis, and (D) elevated baseline lactate dehydrogenase (>upper limit of normal). CI, confidence interval; 
HR, hazard ratio.  
   
 
Table 1. Confirmed RECIST response 
 
 Dabrafenib plus trametinib 
(n=211) 
Dabrafenib plus placebo 
(n=212) 
RECIST response, n (%)   
   Complete response (CR) 38 (18) 31 (15) 
   Partial response (PR) 106 (50) 85 (40) 
   Stable disease 51 (24) 68 (32) 
   Progressive disease 12 (6) 18 (8) 
   Not evaluable 4 (2) 10 (5) 
Response rate (CR+PR), n (%)  
[95% CI]  
144 (68) 
[61.5–74.5] 
116 (55) 
[47.8–61.5] 
Duration of response n=144 n=116 
   Progressed or died, n (%) 100 (69) 84 (72) 
   Median (95% CI), months 12.0 (9.3–17.1) 10.6 (8.3–12.9) 
CI, confidence interval; RECIST, Response Evaluation Criteria In Solid Tumors. 
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